In addition to its well-known anti-inflammatory properties, the tumor-suppressive functions of SIGIRR have been recently described in intestinal cancer and chronic lymphocytic leukemia where SIGIRR is specifically downregulated both at mRNA and protein levels (30, 31). This evidence concerns the gene SIGIRR and B-cell chronic lymphocytic leukemia.